

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:55:32 ON 30 JUN 2008

```
=> file registry
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          0.21        0.21
```

FILE 'REGISTRY' ENTERED AT 11:56:01 ON 30 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2008 HIGHEST RN 1031692-95-1  
DICTIONARY FILE UPDATES: 29 JUN 2008 HIGHEST RN 1031692-95-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> e halofuginone
E1      4      HALOFUGI/BI
E2      4      HALOFUGINON/BI
E3      4 --> HALOFUGINONE/BI
E4      2      HALOG/BI
E5      1      HALOGA/BI
E6      1      HALOGABI/BI
E7      1      HALOGABIDE/BI
E8      151     HALOGEN/BI
E9      132     HALOGENASE/BI
E10     10      HALOGENATE/BI
E11     10      HALOGENATED/BI
E12     1      HALOGENE/BI
```

=> s e3

L1 4 HALOFUGINONE/BI

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.61	5.82

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:56:23 ON 30 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2008 VOL 149 ISS 1  
FILE LAST UPDATED: 29 Jun 2008 (20080629/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l1

L2 323 L1

=> s l1 and (liver or hepatocyte)

323 L1  
592417 LIVER  
38178 LIVERS  
595621 LIVER  
(LIVER OR LIVERS)  
53183 HEPATOCYTE  
46407 HEPATOCYTES  
68647 HEPATOCYTE  
(HEPATOCYTE OR HEPATOCYTES)

L3 47 L1 AND (LIVER OR HEPATOCYTE)

=> s l3 and py<=2002

22935492 PY<=2002

L4 24 L3 AND PY<=2002

=> d l4 ibib abs 1-24

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:600553 CAPLUS

DOCUMENT NUMBER: 138:379131

TITLE: Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats

AUTHOR(S): Spira, Gadi; Mawasi, Nidal; Paizi, Melia; Anbinder, Natali; Genina, Olga; Alexiev, Rosaly; Pines, Mark

CORPORATE SOURCE: Rappaport Family Institute for Research in the Medical Sciences, The Bruce Rappaport Faculty of Medicine, Department of Anatomy and Cell Biology, Technion, Haifa, Israel

SOURCE: Journal of Hepatology (2002), 37(3), 331-339  
CODEN: JOHEEC; ISSN: 0168-8278

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hepatic fibrosis involves excess deposition of extracellular connective tissue of which collagen type I fibers form the predominant component. Left untreated it develops into cirrhosis, often linked with hepatocellular carcinoma. Owing to the fact that cirrhotic liver regeneration is impaired, resection of hepatocellular carcinoma associated with cirrhosis is questionable. The aim of the present study was to determine the potential of halofuginone, a collagen type I inhibitor, in improving liver regeneration in cirrhotic rats. Partial hepatectomy (70%) was performed in thioacetamide-induced cirrhotic rats fed a halofuginone-containing diet. Liver regeneration was monitored by mass and proliferating cell nuclear antigen. The Ishak staging system and hydroxyproline content were used to evaluate the level of fibrosis. Halofuginone administered prior to and following partial hepatectomy did not inhibit normal liver regeneration despite the reduced levels of collagen type I mRNA. When given to rats with established fibrosis, it caused a significant reduction in  $\alpha$  smooth muscle actin, TIMP-2, collagen type I gene expression and collagen deposition. Such animals demonstrated improved capacity for regeneration. Thus, halofuginone may prove useful in improving survival of patients with hepatocellular carcinoma and cirrhosis undergoing surgical resection.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:531106 CAPLUS

DOCUMENT NUMBER: 137:368801

TITLE: Immunoassay and HPLC detection of halofuginone in chicken liver samples obtained from commercial slaughterhouses: a combined study

AUTHOR(S): Beier, Ross C.; Feldman, Steve F.; Dutko, Terry J.; Petersen, H. Delvar; Stanker, Larry H.

CORPORATE SOURCE: Southern Plains Agricultural Research Center, Agricultural Research Service, College Station, TX, 77845-4988, USA

SOURCE: Food and Agricultural Immunology (2002), 14(1), 29-40  
CODEN: FAIMEZ; ISSN: 0954-0105

PUBLISHER: Carfax Publishing

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Halofuginone (Hal) is a feed additive used worldwide to prevent coccidiosis in com. poultry production. The current regulatory method for determining the action level of Hal residues in poultry involves measuring parent Hal in liver tissue by HPLC. A competitive ELISA (cELISA) for Hal was evaluated with respect to HPLC in determining Hal in 473 samples of chicken liver tissue obtained from com. poultry slaughterhouses. Chicken liver samples were divided, and analyzed by both the US Department of Agriculture, Food Safety and Inspection Service's (FSIS's) regulatory method, and by the US Department of Agriculture, Agricultural Research Service's (ARS's) cELISA method described here. The lower level of detection for Hal was 50 ppb by the FSIS HPLC method and 38 ppb by the ARS cELISA method. The lower cutoff limit for this study was 50 ppb as mandated by FSIS SOP. There was good

agreement in the results obtained by HPLC and cELISA. In addition, the cELISA method does not require the use of organic solvents. These data clearly demonstrate that the cELISA method could be used as a screening method for the anal. of Hal in chicken liver tissue. If the cELISA had been used as a screening tool in this study, then only 6 samples ( $\geq 100$  and  $< 160$  ppb) out of the 473 samples analyzed would have required further anal. by HPLC. The organic solvent waste (over 100 l) generated by the HPLC method would have then been reduced to approx. 1.272 l, a considerable time and cost savings in waste management.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:322906 CAPLUS

DOCUMENT NUMBER: 137:179825

TITLE: Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- $\beta$ -mediated Smad3 activation in fibroblasts

AUTHOR(S): McGaha, Tracy L.; Phelps, Robert G.; Spiera, Harry; Bona, Constantin

CORPORATE SOURCE: Department of Microbiology, The Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Journal of Investigative Dermatology (2002), 118(3), 461-470

CODEN: JIDEAE; ISSN: 0022-202X

PUBLISHER: Blackwell Publishing, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Halofuginone is a drug that has been shown to have an antifibrotic property in vitro and in vivo. Whereas halofuginone shows promise as a therapeutic agent for a variety of diseases including scleroderma, liver cirrhosis, cystic fibrosis, and certain types of cancer, the mechanism of action remains unknown. Using the tight skin mouse (TSK) model for scleroderma, we evaluated the ability of halofuginone to inhibit spontaneous development of dermal fibrosis. We found that administration of a low dose of halofuginone both in adult and newborn animals for 60 d prevented the development of cutaneous hyperplasia (dermal fibrosis). In vitro halofuginone was found to reduce the amount of collagen synthesized by fibroblasts. This effect was due to a reduction in the promoter activity of the type-I collagen genes as treatment of fibroblast cultures with  $10^{-8}$  M halofuginone reduced the level of  $\alpha 2(I)$  collagen message detectable by northern blot and greatly reduced the activity of a reporter construct under control of the -3200 to +54 bp  $\alpha 2(I)$  collagen promoter. In addition, anal. of transforming growth factor  $\beta$  signaling pathways in fibroblasts revealed that halofuginone inhibited transforming-growth-factor- $\beta$ -induced upregulation of collagen protein and activity of the  $\alpha 2(I)$  collagen promoter. Further we found that halofuginone blocked the phosphorylation and subsequent activation of Smad3 after transforming growth factor  $\beta$  stimulation. Apparently the inhibitory property was specific to Smad3 as there was no inhibitory effect on the activation of Smad2 after stimulation with transforming growth factor  $\beta$ . Our results demonstrate that halofuginone is a specific inhibitor of type-I collagen synthesis and may elicit its effect via interference with the transforming growth factor  $\beta$  signaling pathway.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:797625 CAPLUS

DOCUMENT NUMBER: 137:118991

TITLE: Pharmacokinetics and tissue distribution of

halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats

AUTHOR(S): Steckclair, Kataleeya P.; Hamburger, Deborah R.; Egorin, Merrill J.; Parise, Robert A.; Covey, Joseph M.; Eiseman, Julie L.

CORPORATE SOURCE: Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA

SOURCE: Cancer Chemotherapy and Pharmacology (2001), 48(5), 375-382  
CODEN: CCPHDZ; ISSN: 0344-5704

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Halofuginone (HF) inhibits synthesis of collagen type I and matrix metalloproteinase-2 and is being considered for clin. evaluation as an antineoplastic agent. Pharmacokinetic studies were performed in the title rodents to define the plasma pharmacokinetics, tissue distribution, and urinary excretion of HF after i.v. delivery and the bioavailability of HF after i.p. and oral delivery. HF was rapidly and widely distributed in rodent tissues and was not converted to detectable metabolites. In mice, HF was 100% bioavailable when given i.p. but could not be detected in plasma after oral administration, suggesting limited oral bioavailability. However, substantial concns. were present in the liver, kidneys, and lungs. HF was present in rat plasma after an oral dose, but the time course and low concns. achieved precluded reliable estimation of bioavailability. These data may assist in designing and interpreting addnl. preclin. and clin. studies of HF.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:703740 CAPLUS

DOCUMENT NUMBER: 135:251986

TITLE: Methods for treating fibroproliferative diseases with antiproliferative or antifibrotic agents, especially antisense c-Jun oligonucleotides

INVENTOR(S): Peterson, Theresa C.

PATENT ASSIGNEE(S): Dalhousie University, Can.

SOURCE: U.S., 13 pp., Cont.-in-part of U.S. 6,025,151.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 6294350	B1	20010925	US 1999-433621	19991102 <--
US 5985592	A	19991116	US 1997-870096	19970605 <--
US 6025151	A	20000215	US 1998-92317	19980605 <--
WO 2001032156	A2	20010510	WO 2000-IB1731	20001102 <--
WO 2001032156	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1997-870096 A2 19970605  
 US 1998-92317 A2 19980605  
 US 1999-433621 A1 19991102

AB In accordance with the present invention, fibroproliferative disease or condition characterized by such symptoms as increased levels of c-Jun homodimers, increased heterodimerization of c-Jun with another signaling peptide, increased levels of phosphorylated c-Jun, or increased presence of Jun kinase are treated by administering to the subject an amount of a compound effective to ameliorate one or more of the symptoms of the disease or condition, for example, an antiproliferative or antifibrotic agent. Preferred compds. for administration according to the invention are antisense c-Jun oligonucleotides and compds. that block c-Jun phosphorylation, such as pentoxifylline, or a functional derivative or metabolite thereof. Also provided by the present invention are in vitro tests for identifying whether a test compound is useful for treatment of a subject afflicted with such a disease and kits useful for conducting such assays.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:338333 CAPLUS  
 DOCUMENT NUMBER: 134:357558  
 TITLE: Methods for treating fibroproliferative diseases  
 INVENTOR(S): Peterson, Theresa C.  
 PATENT ASSIGNEE(S): Dalhousie University, Can.  
 SOURCE: PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032156	A2	20010510	WO 2000-IB1731	20001102 <--
WO 2001032156	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6294350	B1	20010925	US 1999-433621	19991102 <--

PRIORITY APPLN. INFO.: US 1999-433621 A1 19991102  
 US 1997-870096 A2 19970605  
 US 1998-92317 A2 19980605

AB In accordance with the present invention, fibroproliferative disease or condition characterized by such symptoms as increased levels of c-Jun homodimers, increased heterodimerization of c-Jun with another signaling peptide, increased levels of phosphorylated c-Jun, or increased presence of Jun kinase are treated by administering to the subject an amount of a compound effective to ameliorate one or more of the symptoms of the disease or condition, for example, an antiproliferative or antifibrotic agent. Preferred compds. for administration according to the invention are antisense c-Jun oligonucleotides and compds. that block c-Jun phosphorylation, such as pentoxifylline, or a functional derivative or metabolite thereof. Also provided by the present invention are in vitro tests for identifying whether a test compound is useful for treatment of a

subject afflicted with such a disease and kits useful for conducting such assays.

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:122373 CAPLUS

DOCUMENT NUMBER: 135:131807

TITLE: Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats

AUTHOR(S): Bruck, Rafael; Genina, Olga; Aeed, Hussein; Alexiev, Rosaly; Nagler, Arnon; Avni, Yona; Pines, Mark

CORPORATE SOURCE: Department of Gastroenterology, Agricultural Research Organization, Bet Dagan, 50250, Israel

SOURCE: Hepatology (Philadelphia) (2001), 33(2), 379-386

CODEN: HPTLD9; ISSN: 0270-9139

PUBLISHER: W. B. Saunders Co.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hepatic fibrosis is associated with the activation of hepatic stellate cells (HSC), the major source of the extracellular matrix (ECM) proteins. The predominant ECM protein synthesized by the HSC is collagen type I. The authors evaluated the effect of halofuginone - an inhibitor of collagen synthesis - on thioacetamide (TAA)-induced liver fibrosis in rats. In the control rats, the HSC did not express smooth muscle actin, collagen type I gene, or tissue inhibitor of metalloproteinases-2 (TIMP-2), suggesting that they were in their quiescent state. When treated with TAA, the livers displayed large fibrous septa, which were populated by smooth muscle actin-pos. cells expressing high levels of the collagen  $\alpha 1(I)$  gene and containing high levels of TIMP-2, all of which are characteristic of advanced fibrosis. Halofuginone given orally before fibrosis induction prevented the activation of most of the stellate cells and the remaining cells expressed low levels of collagen  $\alpha 1(I)$  gene, resulting in low levels of collagen. The level of TIMP-2 was almost the same as in the control livers. When given to rats with established fibrosis, halofuginone caused almost complete resolution of the fibrotic condition. The levels of collagen, collagen  $\alpha 1(I)$  gene expression, TIMP-2 content, and smooth muscle actin-pos. cells were as in the control rats. Halofuginone inhibited the proliferation of other cell types of the fibrotic liver in vivo and inhibited collagen production and collagen  $\alpha 1(I)$  gene expression in the SV40-immortalized rat HSC-T6 cells in vitro. These results suggest that halofuginone may become an effective and novel mode of therapy in the treatment of liver fibrosis.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:133423 CAPLUS

DOCUMENT NUMBER: 132:161276

TITLE: Extracellular matrix-regulating compounds, including quinazolinones, for inhibition of pathogenic processes related to tissue trauma

INVENTOR(S): Pines, Mark; Vlodavsky, Israel; Nagler, Arnon; Hazum, Eli

PATENT ASSIGNEE(S): Hadasit Medical Research Services and Development Company Ltd., Israel; Agricultural Research Organization

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009070	A2	20000224	WO 1999-IL440	19990813 <--
WO 2000009070	A3	20001019		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2340176	A1	20000224	CA 1999-2340176	19990813 <--
AU 9951914	A	20000306	AU 1999-51914	19990813 <--
AU 756437	B2	20030116		
EP 1109559	A2	20010627	EP 1999-936952	19990813 <--
EP 1109559	B1	20051026		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002522462	T	20020723	JP 2000-564574	19990813 <--
AT 307586	T	20051115	AT 1999-936952	19990813
ES 2255286	T3	20060616	ES 1999-936952	19990813
US 20070010538	A1	20070111	US 2006-402638	20060411
PRIORITY APPLN. INFO.:			IL 1998-125790	A 19980813
			US 1999-137145P	P 19990601
			WO 1999-IL440	W 19990813
			US 2001-762715	B1 20010618

OTHER SOURCE(S): MARPAT 132:161276

GI



AB Compns. and methods are provided to prevent the pathogenic aspects of tissue trauma while preserving normal tissue repair mechanisms, based on the fact that these mols. abrogate the cascade of damage initiated by tissue trauma, while maintaining this the requisite healthy extracellular matrix economy. The composition for regulating the extracellular matrix economy, comprise a pharmaceutically effective amount of an effector in combination with a pharmaceutically acceptable carrier. Preferably, the effector is a quinazolinone derivative. More preferably, the quinazolinone derivative is I wherein (R1 = H, halo, nitro, benzo, lower alkyl, Ph, lower alkoxy; R2 = OH, acetoxy, lower alkoxy; R3 = H, lower alkenoxy; n = 1, 2) and pharmaceutically acceptable salts thereof. Most preferably, the effector is Halofuginone or a pharmaceutically acceptable salt thereof.

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:776630 CAPLUS

DOCUMENT NUMBER: 130:20585

TITLE: Treatment of hepatic cirrhosis

INVENTOR(S): Pines, Mark; Nagler, Arnon

PATENT ASSIGNEE(S): Hadasit Medical Research Services and Development, Israel; Agricultural Research Organization; Friedman,

SOURCE: Mark, M.  
 PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852514	A2	19981126	WO 1998-US10505	19980522 <--
WO 9852514	A3	19990819		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2290502	A1	19981126	CA 1998-2290502	19980522 <--
CA 2290502	C	20070828		
EP 1014988	A2	20000705	EP 1998-924847	19980522 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002515905	T	20020528	JP 1998-550682	19980522 <--
AU 748754	B2	20020613	AU 1998-76922	19980522 <--
IL 132848	A	20040831	IL 1998-132848	19980522
PRIORITY APPLN. INFO.: US 1997-862382 A 19970523 WO 1998-US10505 W 19980522				

OTHER SOURCE(S): MARPAT 130:20585

AB A composition for treating hepatic fibrosis and hepatic cirrhosis, and methods  
 of using and manufacturing the composition are provided. The composition  
 includes a  
 quinazolinone derivative, preferably halofuginone. Examples are given showing  
 the effect of halofuginone on histol. and morphol. of rat liver,  
 effect of halofuginone on mild fibrosis in rat liver, inhibition  
 of fibrosis induced by bile duct ligation, and suitable formulations for  
 administration of halofuginone.

L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:548532 CAPLUS

DOCUMENT NUMBER: 129:170518

ORIGINAL REFERENCE NO.: 129:34509a,34512a

TITLE: Quinazolinone-containing pharmaceutical compositions  
 for prevention of neovascularization and for treating  
 malignancies

INVENTOR(S): Pines, Mark; Nagler, Arnon; Vlodavsky, Israel; Miao,  
 Hua-Quan

PATENT ASSIGNEE(S): Agricultural Research Organization, Israel; Hadasit  
 Medical Research Services and Development Company Ltd.

SOURCE: PCT Int. Appl., 79 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834613	A1	19980813	WO 1998-IL70	19980211 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG

US 6028075	A	20000222	US 1997-797703	19970211 <--
CA 2280850	A1	19980813	CA 1998-2280850	19980211 <--
CA 2280850	C	20040113		
AU 9860049	A	19980826	AU 1998-60049	19980211 <--
AU 738516	B2	20010920		
EP 1007044	A1	20000614	EP 1998-903275	19980211 <--
EP 1007044	B1	20070718		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001518075	T	20011009	JP 1998-534077	19980211 <--
IL 131349	A	20040831	IL 1998-131349	19980211
AT 367158	T	20070815	AT 1998-903275	19980211
ES 2290983	T3	20080216	ES 1998-903275	19980211
US 6420371	B1	20020716	US 2000-479660	20000110 <--
US 39574	E1	20070417	US 2000-742993	20001220
PRIORITY APPLN. INFO.:			US 1997-797703	A 19970211
			WO 1998-IL70	W 19980211
OTHER SOURCE(S):			MARPAT 129:170518	
GI				



AB Compns. are provided for attenuating neovascularization and treating malignancies. The compns. include a pharmaceutically effective amount of I (R1 = H, halo, nitro, benzo, lower alkyl, Ph, lower alkoxy; R2 = OH, acetoxy, lower alkoxy; and R3 = H, lower alkenoxy carbonyl), and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier. Compds. of the invention include Halofuginone and pharmaceutically acceptable salts thereof.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:172859 CAPLUS

DOCUMENT NUMBER: 128:166540

ORIGINAL REFERENCE NO.: 128:32819a, 32822a

TITLE: Detection of Halofuginone Residues in Chicken Liver Tissue by HPLC and a Monoclonal-Based Immunoassay

AUTHOR(S): Beier, Ross C.; Dutko, Terry J.; Buckley, Sandra A.; Muldoon, Mark T.; Holtzapple, Carol K.; Stanker, Larry H.

CORPORATE SOURCE: Food Animal Protection Research Laboratory  
 Agricultural Research Service, U.S. Department of Agriculture, College Station, TX, 77845-9594, USA

SOURCE: Journal of Agricultural and Food Chemistry (1998), 46(3), 1049-1054  
 CODEN: JAFCAU; ISSN: 0021-8561

PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The quinazolinone halofuginone (Hal) is a feed additive used worldwide to prevent coccidiosis in com. poultry production. The current regulatory method for determining the action level of Hal residues in poultry involves measuring parent Hal in liver tissue by HPLC. That procedure is not amenable to high sample throughput due to a complex and tedious sample preparation scheme. A competitive ELISA (cELISA) that can be used as a screening tool for determining Hal in chicken liver tissue is described. The cELISA method was evaluated using standard curves made in both assay buffer and chicken liver extract. The results demonstrated that standard curves made in assay buffer could be used for the cELISA. HPLC vs. cELISA results were obtained during 2 studies; the 1st study used spiked chicken liver tissue, and the 2nd study used both spiked chicken liver tissue and incurred levels of Hal in chicken liver tissue. There was good agreement in the results obtained by HPLC and cELISA. However, in most cases the recovery was higher using the cELISA method than with the HPLC method. In addition, the cELISA method does not require the use of organic solvents. Thus, the cELISA method could be used as a screening method for the anal. of Hal in chicken liver tissue.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:169290 CAPLUS  
DOCUMENT NUMBER: 128:278527  
ORIGINAL REFERENCE NO.: 128:54985a, 54988a  
TITLE: Halofuginone: a novel antifibrotic therapy  
AUTHOR(S): Pines, M.; Nagler, A.  
CORPORATE SOURCE: The Volcani Center, Institute of Animal Science, Agricultural Research Organization, Bet Dagan, 50250, Israel  
SOURCE: General Pharmacology (1998), 30(4), 445-450  
CODEN: GEPHDP; ISSN: 0306-3623  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review with .apprx.60 refs. 1. Fibrosis is characterized by extracellular matrix deposition, of which collagen type I is the major constituent. The progressive accumulation of connective tissue resulted in destruction of normal tissue architecture and function. 2. Fibrosis is a common response to various insults or injuries and can be the outcome of any perturbation in the cellular function of any tissue. 3. Halofuginone was found to inhibit collagen  $\alpha 1(I)$  gene expression and collagen synthesis in a variety of cell cultures including human fibroblasts derived from patients with excessive skin collagen type I synthesis. 4. Halofuginone was found to inhibit collagen  $\alpha 1(I)$  gene expression and collagen synthesis in animal models characterized by excessive deposition of collagen. In these models, fibrosis was induced in various tissues such as skin, liver, lung, etc. Halofuginone was injected i.p., added to the foodstuff or applied locally. 5. Halofuginone decreased skin collagen in a chronic graft-vs.-host disease patient. 6. The ability of extremely low concns. of halofuginone to inhibit collagen  $\alpha 1(I)$  synthesis specifically and transiently at the transcriptional level suggests that this material fulfills the criteria for a successful and effective anti-fibrotic therapy.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:592832 CAPLUS  
DOCUMENT NUMBER: 127:257573  
ORIGINAL REFERENCE NO.: 127:50192h,50193a  
TITLE: Halofuginone, a specific inhibitor of collagen type I  
synthesis, prevents dimethylnitrosamine-induced  
liver cirrhosis  
AUTHOR(S): Pines, Mark; Knopov, Viktor; Genina, Olga; Lavelin,  
Irina; Nagler, Arnon  
CORPORATE SOURCE: The Volcani Center, Institute of Animal Science,  
Agricultural Research Organization, Bet Dagan, 50250,  
Israel  
SOURCE: Journal of Hepatology (1997), 27(2), 391-398  
CODEN: JOHEEC; ISSN: 0168-8278  
PUBLISHER: Munksgaard  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Hepatic cirrhosis is characterized by excessive deposition of collagen, resulting from an increase in type I collagen gene transcription. The authors evaluated the effect of halofuginone - a specific inhibitor of collagen type  $\alpha 1(I)$  gene expression - on dimethylnitrosamine (DMN)-induced liver fibrosis/cirrhosis in rats. Fibrosis was induced by i.p. injection of DMN. Halofuginone (5 mg/kg) was added to the diet. Collagen was stained with Sirius red and collagen  $\alpha 1(I)$  gene expression was evaluated by in situ hybridization. In control rats, a low level of collagen  $\alpha 1(I)$  gene expression was observed. A high dose of DMN (1%) caused severe fibrosis, as indicated by induction of collagen  $\alpha 1(I)$  gene expression and increased liver collagen content. Addition of halofuginone before the onset of fibrosis, almost completely prevented the increase in collagen type I gene expression and resulted in lower liver collagen content. Moreover, halofuginone partially prevented the marked decrease in liver weight and reduced the mortality rate. At a lower dose of DMN (0.25%), which causes mild fibrosis, halofuginone prevented the increase in collagen  $\alpha 1(I)$  gene expression, prevented the increase in liver collagen deposition and reduced plasma alkaline phosphatase activity, all of which are characteristic of liver fibrosis/cirrhosis. These results suggest that halofuginone can be used as an important tool to understand the regulation of the collagen  $\alpha 1(I)$  gene and may become a novel and promising antifibrotic agent for liver fibrosis/cirrhosis.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:393040 CAPLUS  
DOCUMENT NUMBER: 125:85078  
ORIGINAL REFERENCE NO.: 125:16047a,16050a  
TITLE: Residues of halofuginone in tissues of broilers fed  
mixed feeds containing calcium halofuginone  
polystyrene sulfonate  
AUTHOR(S): Ikezawa, Akito; Sato, Yasuhiko; Saito, Norio;  
Ishibashi, Takayuki; Yamaguchi, Yasuki; Kazama, Reiko;  
Obigane, Shigeto  
CORPORATE SOURCE: Fukuoka Fertilizer and Feed Inspection Station,  
Fukuoka, Japan  
SOURCE: Shiryo Kenkyu Hokoku (Tokyo Hishiryo Kensasho) (  
1996), 21, 173-180  
CODEN: SHTKD3; ISSN: 0286-4746  
PUBLISHER: Norin Suisansho Tokyo Hishiryo Kensasho  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese

AB Mixed feeds containing calcium halofuginone polystyrene-sulfonate (HPS) at

concns. authorized for safe use in Japan (40g/ton) were given to broilers by free feeding for 28 days. Afterward, a feed free of HPS was given for 7 days. After slaughter, halofuginone was not detected from any meat tissues of broilers when examined by high performance liquid chromatog., but it was detected in the liver.

L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:373869 CAPLUS  
DOCUMENT NUMBER: 125:56510  
ORIGINAL REFERENCE NO.: 125:10881a,10884a  
TITLE: Detection of halofuginone residues in chicken serum by a monoclonal-based immunoassay and high-performance liquid chromatography  
AUTHOR(S): Beier, Ross C.; Rowe, Loyd D.; Nasr, Magdy I. Abd El-Aziz; Elissalde, Marcel H.; Rose, Beate G.; Stanker, Larry H.  
CORPORATE SOURCE: US Department Agriculture, Agricultural Research Service, College Station, TX, 77845-9594, USA  
SOURCE: Food and Agricultural Immunology (1996), 8(1), 11-17  
CODEN: FAIMEZ; ISSN: 0954-0105  
PUBLISHER: Carfax  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB This study evaluated the usefulness of determining halofuginone (Hal) in chicken

serum with a competitive ELISA (cELISA). If a 4-day withdrawal time could be determined by serum Hal levels, the method would greatly improve on the HPLC methods currently used for Hal detection in liver tissue. A modification of a previously developed HPLC method was used to validate the cELISA anal. of Hal in chicken serum. A serum matrix effect that afforded a higher sensitivity of the cELISA for Hal in chicken serum than in assay buffer or in highly diluted serum was observed. The sensitivity of the cELISA method improved when used in more concentrated serum. The chicken serum samples were evaluated by cELISA, using a standard curve obtained in control chicken serum diluted 2-fold with assay buffer. Incurred levels of Hal in broiler chickens fed Hal-HBr-treated feed were detected in serum after withdrawal times of 2 and 6 h. At and after 24 h, the residues were not detected by immunoassay with a detection limit of 0.52 ppb or by HPLC with detection limit of 0.86 ppb. The instability of Hal in acidified serum and its potential for methanolysis in the HPLC method were overcome by using the cELISA methodol. Although the determination of Hal in chicken serum

by

immunoassay is fast, requiring no clean-up steps, chicken serum cannot be used to determine the required 4-day withdrawal time in broiler chickens because of the lack of residues in the serum at and after 24 h.

L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:578121 CAPLUS  
DOCUMENT NUMBER: 121:178121  
ORIGINAL REFERENCE NO.: 121:32343a,32346a  
TITLE: Levels of coccidiostats in chicken tissues after feeding medicated feed  
AUTHOR(S): Tarbin, J. A.; Chapman, S.; Farrington, W. H. H.; Patey, A. L.; Shearer, G.  
CORPORATE SOURCE: Food Saf. Dir., Minist. Agric. Fish. and Food, Food Sci. Lab., Norwich, NR4 7UQ, UK  
SOURCE: Residues Vet. Drugs Food, Proc. EuroResidue Conf., 2nd (1993), Volume 2, 655-8. Editor(s): Haagsma, N.; Ruiter, A.; Czedik-Eysenberg, Peter B. Utrecht Univ. Fac. Vet. Med.: Utrecht, Neth.  
CODEN: 60CDAT

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Over a period of 46 days, chickens were fed monensin, narasin, salinomycin and halofuginone at the com. dose. Tissues of birds slaughtered after 0, 1, 2 and 3 days withdrawal were analyzed for residues. Monensin, narasin and salinomycin were quantified by HPTLC. Halofuginone was quantified by HPLC. Residues of all four coccidiostats were found in all tissues analyzed after 0 days withdrawal. Levels of monensin, narasin and salinomycin decreased to below the detection limit after 1 day withdrawal. Levels of halofuginone reduced to below 0.010 mg kg<sup>-1</sup> after 1 day withdrawal in muscle tissue.

L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:424899 CAPLUS

DOCUMENT NUMBER: 117:24899

ORIGINAL REFERENCE NO.: 117:4481a,4484a

TITLE: Tolerances for residues of new animal drugs in food; halofuginone hydrobromide

CORPORATE SOURCE: United States Food and Drug Administration, Rockville, MD, 20857, USA

SOURCE: Federal Register (1992), 57(97), 21209, 19 May 1992

CODEN: FEREAC; ISSN: 0097-6326

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The marker residue for Stenorol (halofuginone-HBr) in turkey liver is amended to 0.13 ppm, under the Federal Food, Drug, and Cosmetic Act.

L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:127159 CAPLUS

DOCUMENT NUMBER: 116:127159

ORIGINAL REFERENCE NO.: 116:21505a,21508a

TITLE: Simple determination of halofuginone in chicken tissue by high performance liquid chromatography

AUTHOR(S): Yamamoto, Yuzo; Hashiguchi, Reiko; Araki, Keiko; Kushima, Hirofumi

CORPORATE SOURCE: Miyazaki Prefect. Inst. Public Health Environ., Miyazaki, 889-21, Japan

SOURCE: Shokuhin Eiseigaku Zasshi (1991), 32(5), 444-7

CODEN: SKEZAP; ISSN: 0015-6426

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Halofuginone in chicken tissue is determined by extraction with acetate buffer-MeOH, concentration, extraction with AcOEt and HPLC using MeCN-acetate buffer-H<sub>2</sub>O containing tetra-n-BuNBr. The recoveries in chicken muscle, liver and egg were 87, 64 and 64%, resp.

L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:162567 CAPLUS

DOCUMENT NUMBER: 114:162567

ORIGINAL REFERENCE NO.: 114:27479a,27482a

TITLE: Tolerances for residues of new animal drugs in food; halofuginone hydrobromide

CORPORATE SOURCE: United States Food and Drug Administration, Rockville, MD, 20857, USA

SOURCE: Federal Register (1991), 56(41), 8710-11, 1 Mar 1991

CODEN: FEREAC; ISSN: 0097-6326

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Stenorol (halofuginone-HBr) may be used in poultry feed for the prevention of coccidiosis, under the Federal Food, Drug, and Cosmetic Act, and tolerances of 0.16 and 0.1 ppm are established for parent halofuginone-HBr in livers of broilers and turkeys, resp. These marker residue concns. correspond to total residue concns. of 0.3 ppm in liver.

L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:513897 CAPLUS

DOCUMENT NUMBER: 111:113897

ORIGINAL REFERENCE NO.: 111:19095a,19098a

TITLE: Animal drugs, feeds, and related products;  
halofuginone

CORPORATE SOURCE: United States Food and Drug Administration, Rockville,  
MD, 20857, USA

SOURCE: Federal Register (1989), 54(127), 28051-3, 5  
Jul 1989

CODEN: FEREAC; ISSN: 0097-6326

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Halofuginone-HBr (I) type A medicated articles may be used to prepare medicated feeds containing 1.36-2.72 g I/ton for prevention of coccidiosis in turkeys, under the Federal Food, Drug, and Cosmetic Act. The tolerance for I in liver is 0.1 ppm, which corresponds to 0.3 ppm total I in liver. The safe concns. of I in turkey are: muscle 0.1, liver 0.3, and skin with s.c. fat 0.2 ppm.

L4 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:532322 CAPLUS

DOCUMENT NUMBER: 105:132322

ORIGINAL REFERENCE NO.: 105:21337a,21340a

TITLE: Residue test of calcium halofuginone  
polystyrenesulfonate in broiler chickens

AUTHOR(S): Murano, Takako; Uchino, Takeshi; Ino, Rinpei

CORPORATE SOURCE: Div. Poult. Farming, Livest. Cent. Chiba Prefect.,  
289-11, Japan

SOURCE: Kenkyu Hokoku - Chiba-ken Chikusan Senta (1985  
, (9), 31-7

CODEN: KHCSDO; ISSN: 0386-5673

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Feeds which contained 40, 80, and 120 ppm Ca halofuginone poly(styrenesulfonate) (CHP) were repeatedly administered to broiler chickens and the residual rates of CHP in several organs were studied. The concns. of CHP in liver, kidney, skin, muscle, fat and blood were below detection limits 7, 7, 5, 3, 2 and 2 days after repeated administration at all concns. of CHP, resp. CHP apparently did not remain in any organ of broiler chickens for a long time.

L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1985:540456 CAPLUS

DOCUMENT NUMBER: 103:140456

ORIGINAL REFERENCE NO.: 103:22485a,22488a

TITLE: Tolerances for residues of new animal drugs in food;  
new animal drugs for use in animal feeds; halofuginone  
hydrobromide

AUTHOR(S): Gabuten, Adriano

CORPORATE SOURCE: Cent. Vet. Med., Food Drug Adm., Rockville, MD, 20857,  
USA

SOURCE: Federal Register (1985), 50(162), 33718-19,  
21 Aug 1985

CODEN: FEREAC; ISSN: 0097-6326



DOCUMENT TYPE: Journal

LANGUAGE: English

AB Halofuginone-HBr [64924-67-0] may be fed to broiler chickens to prevent coccidiosis, and tolerances of 0.1 ppm for parent halofuginone [55837-20-2] and 0.3 ppm for total residues is established for liver, under the Federal Food, Drug, and Cosmetic Act. The feed may contain 2.72 g halofuginone-Hbr/ton, and must be withdrawn 4 days before slaughter.

L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:405595 CAPLUS

DOCUMENT NUMBER: 101:5595

ORIGINAL REFERENCE NO.: 101:967a,970a

TITLE: Collaborative study of a method for the determination of residues of halofuginone in chicken tissue

CORPORATE SOURCE: Analytical Methods Committee, R. Soc. Chem., UK

SOURCE: Analyst (Cambridge, United Kingdom) (1984), 109(2), 171-4

CODEN: ANALAO; ISSN: 0003-2654

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The halofuginone [55837-20-2] is extracted as the free base with EtOAc after digestion of chicken tissues with trypsin and then partitioned into an aqueous NH4OAc buffer. After further clean-up and concentration using

a Sep-Pak C18 cartridge, the extract is examined by high-performance liquid chromatog. using a reversed-phase column and a UV detector. The procedure was tested by carrying out procedural recoveries from spiked samples and also by a collaborative exercise using samples of tissues from birds fed on a diet containing halofuginone. The efficiency of the extraction procedure

was assessed by using samples of a chicken that had been fed with 14C-labeled halofuginone.

L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:568302 CAPLUS

DOCUMENT NUMBER: 91:168302

ORIGINAL REFERENCE NO.: 91:27021a,27024a

TITLE: Factors influencing the assessment of anticoccidial activity in cell culture

AUTHOR(S): Latter, Victoria S.; Wilson, R. G.

CORPORATE SOURCE: Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK


SOURCE: Parasitology (1979), 79(1), 169-75

CODEN: PARAAE; ISSN: 0031-1820

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A comparative study was made of the factors influencing the assessment of anticoccidial potency in vitro against Eimeria tenella using established

anticoccidials and arprinocid (I) [55779-18-5] and some of its analogs. Drugs whose potency depended upon medium composition were amprolium [121-25-5], lasalocid [11054-70-9], and halofuginone [55837-20-2]. There was a difference in strain sensitivity with robenidine [25875-51-8]. Host cell type had an important effect on potency of monensin [17090-79-8], decoquinate [18507-89-6], and I and its analogs. I was active in chick liver cell systems but totally inactive in chick kidney cell systems, although its N-oxide was active in both cell types. I-containing medium, conditioned by supporting the growth of chick embryo liver cell cultures, had an anticoccidial effect on E. tenella growing in chick kidney cells. Thus, the anticoccidial activity of I in the chick is due to a metabolite.

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching

NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option

NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts

NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents

NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications

NEWS 28 JUN 19 CAS REGISTRY includes selected substances from web-based collections

NEWS 29 JUN 25 CA/CAPLUS and USPAT databases updated with IPC reclassification data

NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records

NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations

NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in

NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:50:26 ON 08 JUL 2008

=> file medline caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 08:50:57 ON 08 JUL 2008

FILE 'CAPLUS' ENTERED AT 08:50:57 ON 08 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s halofuginone and (liver or hepatocyte) and regenerat?

L1 7 HALOFUGINONE AND (LIVER OR HEPATOCYTE) AND REGENERAT?

=> d l1 ibib abs 1-7

L1 ANSWER 1 OF 7 MEDLINE on STN

ACCESSION NUMBER: 2008333929 MEDLINE

DOCUMENT NUMBER: PubMed ID: 18458672

TITLE: Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats.

AUTHOR: Ohayon Olga; Mawasi Nidal; Pevzner Anna; Tryvitz Ana; Gildor Tsvia; Pines Mark; Rojkind Marcos; Paizi Melia; Spira Gadi

CORPORATE SOURCE: Department of Anatomy and Cell Biology, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

CONTRACT NUMBER: AA09231 (United States NIAAA)  
R01 AA10541 (United States NIAAA)

SOURCE: Laboratory investigation; a journal of technical methods and pathology, (2008 Jun) Vol. 88, No. 6, pp. 627-33.  
Electronic Publication: 2008-05-05.  
Journal code: 0376617. E-ISSN: 1530-0307.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200806

ENTRY DATE: Entered STN: 24 May 2008  
Last Updated on STN: 11 Jun 2008  
Entered Medline: 10 Jun 2008

AB Advanced hepatic fibrosis is characterized by excessive extracellular matrix deposition, where collagen and proteoglycans are the main constituents of scar tissue. In previous studies, we showed that heparanase, a heparan sulfate-degrading enzyme, and vascular endothelial growth factor (VEGF) play an important role during liver development and remodeling. In this communication, we investigated the relationship between heparanase and VEGF in thioacetamide-induced liver fibrosis in rats. Our study shows that heparanase mRNA expression levels correlate with those of VEGF during the induction and recovery stages of liver fibrosis. We further demonstrated that treating fibrotic rat livers with halofuginone (HF), a multipotent antifibrogenic drug, and subsequently subjecting them to hydrodynamics-based transfection with human VEGF-165 resulted in elevated expression of heparanase mRNA. Moreover, these rats demonstrated an improved capacity to regenerate following 70% partial hepatectomy. In vitro, HF stimulated heparanase and VEGF mRNA expression in hepatic stellate cells. Taken together, our results suggest that in addition to the known multiple functions of HF, it also enhances heparanase and VEGF expression and promotes liver regeneration. Accordingly, HF seems to possess ideal properties required to become an excellent antifibrogenic agent in humans.

L1 ANSWER 2 OF 7 MEDLINE on STN

ACCESSION NUMBER: 2006230955 MEDLINE

DOCUMENT NUMBER: PubMed ID: 16508789

TITLE: Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone.

AUTHOR: Gnainsky Yulia; Spira Gadi; Paizi Melia; Bruck Raffael; Nagler Arnon; Genina Olga; Taub Rebbeca; Halevy Orna; Pines Mark

CORPORATE SOURCE: Institute of Animal sciences , Volcani Center , P.O. Box 6 , 50250 Bet Dagan , Israel.

SOURCE: Cell and tissue research, (2006 Jun) Vol. 324, No. 3, pp. 385-94. Electronic Publication: 2006-03-01.  
Journal code: 0417625. ISSN: 0302-766X.

PUB. COUNTRY: Germany: Germany, Federal Republic of

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200704  
ENTRY DATE: Entered STN: 27 Apr 2006  
Last Updated on STN: 11 Apr 2007  
Entered Medline: 10 Apr 2007

AB Tyrosine phosphatase PRL-1 is one of the immediate-early genes up-regulated during liver regeneration and is apparently involved in cell proliferation. Previously, we have demonstrated that halofuginone, an inhibitor of collagen type I synthesis, prevents liver fibrosis and improves cirrhotic liver regeneration. In this study, we evaluated the effect of halofuginone on PRL-1 expression, its cellular localization in vitro and during liver regeneration, and fibrosis progression in vivo. In culture, halofuginone increased PRL-1 expression in primary rat hepatocytes and in hepatocellular carcinoma (HCC) cell lines, the former being more sensitive to halofuginone. The halofuginone-dependent increase in PRL-1 gene expression was correlated with an increase in the transcription factor early growth response-1 (Egr-1) and inversely correlated with the inhibition of cell proliferation. Halofuginone arrested HepG2 and Huh7 cell lines at the G1 phase, whereas Hep3B cells were arrested at G2/M, probably because of a reduction in the synthesis of cyclins D1 and B1 in all HCC cells and increased cyclin A in Hep3B cells. Halofuginone also affected the PRL-1 sub-cellular localization that was cell-cycle-dependent. In addition, halofuginone augmented PRL-1 expression in the remnant liver after partial hepatectomy and in chemically induced fibrosis in rats; this was accompanied by increased expression of insulin-like growth factor binding protein 1 (IGFBP-1), another immediate-early gene of regeneration. The regulation of the expression of the early genes of regeneration such as PRL-1 and IGFBP-1 is thus part of the mode of action of halofuginone and results in the prevention of liver fibrosis and improved cirrhotic liver regeneration.

L1 ANSWER 3 OF 7 MEDLINE on STN  
ACCESSION NUMBER: 2002422182 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 12175628  
TITLE: Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats.  
AUTHOR: Spira Gadi; Mawasi Nidal; Paizi Melia; Anbinder Natali; Genina Olga; Alexiev Rosaly; Pines Mark  
CORPORATE SOURCE: Department of Anatomy and Cell Biology, The Bruce Rappaport Faculty of Medicine, Rappaport Family Institute for Research in the Medical Sciences, Technion, Haifa, Israel.. spira@tx.technion.ac.il  
SOURCE: Journal of hepatology, (2002 Sep) Vol. 37, No. 3, pp. 331-9.  
Journal code: 8503886. ISSN: 0168-8278.  
PUB. COUNTRY: England: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200304  
ENTRY DATE: Entered STN: 15 Aug 2002  
Last Updated on STN: 8 Apr 2003  
Entered Medline: 7 Apr 2003

AB BACKGROUND/AIMS: Hepatic fibrosis involves excess deposition of extracellular connective tissue of which collagen type I fibers form the

predominant component. Left untreated it develops into cirrhosis, often linked with hepatocellular carcinoma. Owing to the fact that cirrhotic liver regeneration is impaired, resection of hepatocellular carcinoma associated with cirrhosis is questionable. The aim of the present study was to determine the potential of halofuginone, a collagen type I inhibitor, in improving liver regeneration in cirrhotic rats. METHODS: Partial hepatectomy (70%) was performed in thioacetamide-induced cirrhotic rats fed a halofuginone-containing diet. Liver regeneration was monitored by mass and proliferating cell nuclear antigen. The Ishak staging system and hydroxyproline content were used to evaluate the level of fibrosis. RESULTS: Halofuginone administered prior to and following partial hepatectomy did not inhibit normal liver regeneration despite the reduced levels of collagen type I mRNA. When given to rats with established fibrosis, it caused a significant reduction in alpha smooth muscle actin, TIMP-2, collagen type I gene expression and collagen deposition. Such animals demonstrated improved capacity for regeneration. CONCLUSIONS: Halofuginone may prove useful in improving survival of patients with hepatocellular carcinoma and cirrhosis undergoing surgical resection.

L1 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:620354 CAPLUS

TITLE: Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats

AUTHOR(S): Ohayon, Olga; Mawasi, Nidal; Pevzner, Anna; Tryvitz, Ana; Gildor, Tsvia; Pines, Mark; Rojkind, Marcos; Paizi, Melia; Spira, Gadi

CORPORATE SOURCE: Department of Anatomy and Cell Biology, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

SOURCE: Laboratory Investigation (2008), 88(6), 627-633  
CODEN: LAINAW; ISSN: 0023-6837

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Advanced hepatic fibrosis is characterized by excessive extracellular matrix deposition, where collagen and proteoglycans are the main constituents of scar tissue. In previous studies, we showed that heparanase, a heparan sulfate-degrading enzyme, and vascular endothelial growth factor (VEGF) play an important role during liver development and remodeling. In this communication, we investigated the relationship between heparanase and VEGF in thioacetamide-induced liver fibrosis in rats. Our study shows that heparanase mRNA expression levels correlate with those of VEGF during the induction and recovery stages of liver fibrosis. We further demonstrated that treating fibrotic rat livers with halofuginone (HF), a multipotent antifibrogenic drug, and subsequently subjecting them to hydrodynamics-based transfection with human VEGF-165 resulted in elevated expression of heparanase mRNA. Moreover, these rats demonstrated an improved capacity to regenerate following 70% partial hepatectomy. In vitro, HF stimulated heparanase and VEGF mRNA expression in hepatic stellate cells. Taken together, our results suggest that in addition to the known multiple functions of HF, it also enhances heparanase and VEGF expression and promotes liver regeneration. Accordingly, HF seems to possess ideal properties required to become an excellent antifibrogenic agent in humans. Laboratory Investigation (2008) 88, 627-633; doi:10.1038/labinvest.2008.30; published online 5 May 2008.

L1 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:390410 CAPLUS

DOCUMENT NUMBER: 145:369747  
TITLE: Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone  
AUTHOR(S): Gnainsky, Yulia; Spira, Gadi; Paizi, Melia; Bruck, Raffael; Nagler, Arnon; Genina, Olga; Taub, Rebecca; Halevy, Orna; Pines, Mark  
CORPORATE SOURCE: Institute of Animal sciences, Volcani Center, Bet Dagan, 50250, Israel  
SOURCE: Cell & Tissue Research (2006), 324(3), 385-394  
CODEN: CTSRCS; ISSN: 0302-766X  
PUBLISHER: Springer  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Tyrosine phosphatase PRL-1 is one of the immediate-early genes up-regulated during liver regeneration and is apparently involved in cell proliferation. Previously, we have demonstrated that halofuginone, an inhibitor of collagen type I synthesis, prevents liver fibrosis and improves cirrhotic liver regeneration. In this study, we evaluated the effect of halofuginone on PRL-1 expression, its cellular localization in vitro and during liver regeneration, and fibrosis progression in vivo. In culture, halofuginone increased PRL-1 expression in primary rat hepatocytes and in hepatocellular carcinoma (HCC) cell lines, the former being more sensitive to halofuginone. The halofuginone-dependent increase in PRL-1 gene expression was correlated with an increase in the transcription factor early growth response-1 (Egr-1) and inversely correlated with the inhibition of cell proliferation. Halofuginone arrested HepG2 and Huh7 cell lines at the G1 phase, whereas Hep3B cells were arrested at G2/M, probably because of a reduction in the synthesis of cyclins D1 and B1 in all HCC cells and increased cyclin A in Hep3B cells. Halofuginone also affected the PRL-1 sub-cellular localization that was cell-cycle-dependent. In addition, halofuginone augmented PRL-1 expression in the remnant liver after partial hepatectomy and in chemical induced fibrosis in rats; this was accompanied by increased expression of insulin-like growth factor binding protein 1 (IGFBP-1), another immediate-early gene of regeneration. The regulation of the expression of the early genes of regeneration such as PRL-1 and IGFBP-1 is thus part of the mode of action of halofuginone and results in the prevention of liver fibrosis and improved cirrhotic liver regeneration.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:387228 CAPLUS  
DOCUMENT NUMBER: 140:386059  
TITLE: Quinazolinone compositions for regulation of gene expression related to pathological processes  
INVENTOR(S): Pines, Mark; Nagler, Arnon; Yarkoni, Shai  
PATENT ASSIGNEE(S): State of Israel, Ministry of Agriculture, Israel; Hadasit Medical Research Services and Development Ltd.; Collgard Biopharmaceuticals Ltd.  
SOURCE: PCT Int. Appl., 49 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004039308	A2	20040513	WO 2003-IL900	20031030
WO 2004039308	A3	20040708		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2504388	A1	20040513	CA 2003-2504388	20031030
AU 2003278579	A1	20040525	AU 2003-278579	20031030
EP 1558261	A2	20050803	EP 2003-769875	20031030
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006504769	T	20060209	JP 2004-547952	20031030
US 20060258692	A1	20061116	US 2006-533371	20060601
PRIORITY APPLN. INFO.:			US 2002-422487P	P 20021031
			WO 2003-IL900	W 20031030

OTHER SOURCE(S): MARPAT 140:386059

AB The invention discloses pharmaceutical compns. for modifying gene expression in a pathol. process, thereby preventing or ameliorating the process. More particularly the compns. comprise quinazolinones, especially halofuginone, for inhibiting or preventing alterations in gene expression during fibrosis. The invention particularly relates to pharmaceutical compns. for improving the regeneration of cirrhotic liver.

L1 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:600553 CAPLUS

DOCUMENT NUMBER: 138:379131

TITLE: Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats

AUTHOR(S): Spira, Gadi; Mawasi, Nidal; Paizi, Melia; Anbinder,

CORPORATE SOURCE: Natali; Genina, Olga; Alexiev, Rosaly; Pines, Mark Rappaport Family Institute for Research in the Medical Sciences, The Bruce Rappaport Faculty of Medicine, Department of Anatomy and Cell Biology, Technion, Haifa, Israel

SOURCE: Journal of Hepatology (2002), 37(3), 331-339

CODEN: JOHEEC; ISSN: 0168-8278

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hepatic fibrosis involves excess deposition of extracellular connective tissue of which collagen type I fibers form the predominant component. Left untreated it develops into cirrhosis, often linked with hepatocellular carcinoma. Owing to the fact that cirrhotic liver regeneration is impaired, resection of hepatocellular carcinoma associated with cirrhosis is questionable. The aim of the present study was to determine the potential of halofuginone, a collagen type I inhibitor, in improving liver regeneration in cirrhotic rats. Partial hepatectomy (70%) was performed in thioacetamide-induced cirrhotic rats fed a halofuginone-containing diet. Liver regeneration was monitored by mass and proliferating cell nuclear antigen. The Ishak staging system and



hydroxyproline content were used to evaluate the level of fibrosis. Halofuginone administered prior to and following partial hepatectomy did not inhibit normal liver regeneration despite the reduced levels of collagen type I mRNA. When given to rats with established fibrosis, it caused a significant reduction in  $\alpha$  smooth muscle actin, TIMP-2, collagen type I gene expression and collagen deposition. Such animals demonstrated improved capacity for regeneration. Thus, halofuginone may prove useful in improving survival of patients with hepatocellular carcinoma and cirrhosis undergoing surgical resection.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	21.65	21.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 08:52:37 ON 08 JUL 2008